Introduction
Gene panel sequencing has emerged as a cornerstone of modern genomics, offering targeted analysis of specific gene sets with high precision and efficiency. It plays a pivotal role in disease diagnosis, personalized treatment planning, and biomedical research, enabling clinicians and researchers to gain actionable insights from genetic data. As applications continue to expand across healthcare and research settings, understanding the purpose, benefits, and practical uses of gene panel sequencing is essential for professionals in the field. This article explores what gene panel sequencing entails, why it is used, and how it is applied across clinical and scientific research.
What is Gene Panel Sequencing?
Gene panel sequencing is a Next-Generation Sequencing (NGS) approach that targets a predefined group of genes associated with specific diseases or biological pathways. Instead of sequencing the entire genome or exome, this approach focuses only on genes of clinical or research-relevance, making it a cost-effective and efficient alternative for diagnostic laboratories and l research institutions.
Laboratories can choose between custom or pre-designed gene panels depending on their validation, variant interpretation, or research needs.
- Custom panels allow researchers and clinicians to tailor gene selection for specific diseases or phenotypes.
- Pre-designed panels streamline standardization and validation, ensuring compliance with ISO 13485 standards, which are a prerequisite for IVDR certification.
Purpose and Advantages of Gene Panel Sequencing
Gene panel sequencing plays a critical role in clinical and research settings by enabling the targeted analysis of specific disease-associated genes. Unlike whole genome sequencing, which generates vast amounts of genetic data, gene panel sequencing focuses only on relevant genes, reducing unnecessary data and simplifying downstream analysis. This targeted approach enhances diagnostic precision and streamlines treatment decision-making.
One of the key advantages of gene panel sequencing is its faster turnaround time for clinical reporting. Since the sequencing process is limited to a predefined set of genes, laboratories can process results more efficiently, making it ideal for high-throughput diagnostic workflows. Faster results enable clinicians to make timely decisions, improving patient management and personalized treatment planning.
Standardization and reproducibility are also enhanced through gene panel sequencing, as the technique ensures consistent validation across laboratories. To ensure standardized variant classification and reporting, laboratories conducting gene panel sequencing have to comply with guidelines established by the American College of Medical Genetics and Genomics (ACMG), the Association for Molecular Pathology (AMP), and the College of American Pathologists (CAP). These frameworks define best practices for interpreting genetic variants, ensuring consistency and reliability in clinical reporting. Additionally, adherence to international regulatory standards such as ISO 13485 and In Vitro Diagnostic Regulation (IVDR) is required for laboratories developing and using diagnostic tests. Tools like omnomicsV support the validation of sequencing data, while omnomicsNGS facilitates variant interpretation, ensuring compliance with these standards.
Maintaining high-quality assurance in gene panel sequencing is important for clinical reliability. Automated systems such as omnomicsQ continuously monitor genomic samples, flagging those that do not meet pre-defined quality thresholds. Participation in external quality assessment (EQA) programs, such as EMQN and GenQA, further improves cross-laboratory standardization, ensuring that results remain reproducible and clinically valid.
By integrating gene panel sequencing into clinical workflows, healthcare providers gain a powerful tool for diagnosing hereditary conditions, guiding cancer treatment, optimizing pharmacogenomic therapies, and ensuring compliance with strict industry standards.
Clinical Applications of Gene Panel Sequencing
One important application is the diagnosis of hereditary diseases, where gene panel sequencing is used to detect pathogenic variants associated with inherited disorders. Identifying these genetic variants allows for early detection of disease, enabling healthcare providers to take preventive actions or begin treatment before symptoms appear.
This approach also supports informed family planning. Individuals who carry disease-related mutations can evaluate potential reproductive risks and consider options such as genetic counseling or preimplantation genetic testing.
In oncology and cancer genomics, gene panel sequencing is vital for detecting somatic and germline mutations. This data enables personalized treatment by helping clinicians select targeted therapies or immunotherapies tailored to a tumor’s specific genetic profile.
For example, mutations in the BRCA1 and BRCA2 genes are widely used to assess an individual’s risk of developing breast and ovarian cancers. Similarly, pathogenic variants in MLH1, MSH2, MSH6, and PMS2 are associated with Lynch syndrome, a hereditary condition that significantly increases the risk of colorectal and other cancers. The growing clinical relevance of gene panel testing is reflected in the development of comprehensive diagnostic tools, such as the Invitae Common Hereditary Cancers Panel, which analyzes multiple genes linked to hereditary cancer susceptibility.
Another important application of gene panel sequencing is pharmacogenomics, which aims to optimize drug therapy based on a patient’s genetic profile. By identifying genetic variations that affect drug metabolism and response, clinicians can better predict how patients will react to specific medications. This enables the selection of the most appropriate drug and dosage while minimizing the risk of adverse drug reactions.
For instance, variations in genes encoding enzymes of the cytochrome P450 system can significantly influence the metabolism of commonly prescribed medications, including anticoagulants and antidepressants. Incorporating this genetic information into clinical decision-making supports personalized treatment strategies and improves both the safety and effectiveness of drug therapy.
Research Applications of Gene Panel Sequencing
Understanding gene function is essential for elucidating the molecular mechanisms underlying disease. Gene panel sequencing enables the investigation of genetic pathways and interactions, helping researchers identify the roles of specific genes in both normal biological processes and disease states.
This approach allows researchers to analyze targeted sets of genes associated with particular biological pathways, facilitating discoveries related to inherited disorders, cancer development, and rare genetic diseases. By examining how genetic variants influence protein function and cellular processes, researchers can gain valuable insights that may contribute to the development of new therapeutic strategies. Accurate variant classification and data interpretation require advanced bioinformatics tools capable of processing and analyzing the large volumes of genomic data generated by sequencing technologies.
Platforms like omnomicsNGS support this process by integrating multi-source annotations, ensuring that variant classifications remain consistent and up to date. These platforms streamline the interpretation of genetic data by incorporating information from databases such as ClinVar and CIViC, reducing the manual workload while improving accuracy. Automated re-evaluation of stored variants ensures that previously analyzed data reflects the latest scientific findings, which is important for maintaining reliable research outcomes.
Gene panel sequencing also plays an important role in large-scale population studies by providing scalable sequencing strategies for epidemiological and genomic research. By applying gene panels to large cohorts of individuals, researchers can investigate how genetic variation contributes to disease risk across diverse populations. This approach is particularly valuable in population-based genetic screening programs, where identifying disease-associated variants can inform public health strategies and preventive interventions.
Large-scale sequencing efforts enable researchers to assess genetic diversity, detect mutations associated with inherited conditions, and improve risk prediction models using population-level genetic data. These studies help reveal patterns of genetic variation within and between populations, contributing to a better understanding of disease susceptibility and genetic risk factors.
Overall, gene panel sequencing supports large-scale population research by enabling targeted investigation of disease-related genes, improving variant interpretation, and advancing our understanding of the genetic basis of disease across populations.
Technical Aspects of Gene Panel Sequencing
Understanding the technical aspects of gene panel sequencing is important for ensuring accurate, reliable, and scalable genomic analysis. The efficiency and quality of sequencing depend on well-structured panel design, robust variant interpretation, seamless IT integration, and adherence to external quality assessment (EQA) programs.
Effective panel design starts with selecting target genes based on clinical relevance. The goal is to ensure high coverage and specificity, capturing genes associated with the disease or condition being investigated. This involves balancing panel size with sequencing depth and avoiding unnecessary genes that could weaken analytical sensitivity. Additionally, designing panels with flexibility allows laboratories to update them as new genetic insights emerge.
Interpreting variants presents major computational challenges. Genomic data require secondary analysis pipelines capable of handling large datasets efficiently. Tools such as omnomicsNGS streamline variant interpretation by integrating multiple annotation sources and filtering strategies. This automation minimizes manual effort while ensuring compliance with guidelines from organizations like ACMG and CAP. Also, quality control tools like omnomicsQ provide real-time monitoring of sequencing runs, flagging samples that do not meet predefined quality thresholds. This proactive approach prevents downstream errors and ensures only high-quality data proceed to analysis. The validation tools like omnomicsV help laboratories verify assay performance, ensuring that variant detection meets required sensitivity and specificity thresholds. Additionally, seamless integration with laboratory IT systems is critical to maintaining workflow efficiency and regulatory compliance. Laboratories have to ensure that sequencing data flows smoothly between sequencing platforms, LIMS (Laboratory Information Management Systems), and healthcare IT infrastructures. Compliance with data protection regulations such as GDPR, HIPAA, and IVDR is non-negotiable. While GDPR and HIPAA focus on safeguarding patient data, IVDR ensures that diagnostic products meet safety and performance standards. Laboratories using ISO 13485-compliant tools meet these regulatory requirements while maintaining high operational standards.
Limitations and Ethical Considerations in Gene Panel Sequencing
Despite its advantages, gene panel sequencing has several important limitations that must be considered in both research and clinical settings. Because panels target a predefined set of genes, they may fail to detect pathogenic variants in genes not included, including novel or unexpected disease-associated genes. Certain types of genetic alterations—such as large structural variants, copy number variations, repeat expansions, and deep intronic or regulatory mutations—may also go undetected depending on the panel design and sequencing technology. Interpreting results can be challenging, as many variants are classified as variants of uncertain significance (VUS), requiring additional functional studies, family segregation analyses, or reference to population databases for accurate classification. Population bias is another concern, since panels are often developed based on data from specific ethnic groups, potentially reducing accuracy and leading to misclassification in underrepresented populations. Technical factors, including low-quality DNA, uneven sequencing coverage, and potential sequencing errors, can further compromise result reliability. Moreover, gene panels must be regularly updated to incorporate newly discovered disease-associated genes; otherwise, older panels may provide incomplete or outdated information.
While panels are more cost-effective and faster than whole-exome or whole-genome sequencing, their narrow focus limits their ability to capture the full spectrum of genetic variation, which may be critical in complex, atypical, or multifactorial cases.Gene panel sequencing raises important ethical, regulatory, and quality considerations. Handling genomic data requires compliance with frameworks such as GDPR in Europe and HIPAA in the United States, which protect patient privacy and enforce data security. Ensuring standardization and reproducibility across laboratories is also critical, as variations in sequencing protocols, bioinformatics pipelines, and data interpretation can affect results. Laboratories address these challenges through validated workflows, automated quality control, and participation in external quality assessment programs. Additionally, gene panel sequencing can reveal incidental findings, highlighting the need for clear policies on informed consent, genetic counseling, and responsible reporting to protect patient autonomy and well-being. Emerging regulations, such as the IVDR in the EU, will further formalize standards for diagnostic test performance once fully implemented.
Conclusion
Gene panel sequencing is both a targeted and efficient approach to genetic analysis. Its ability to focus on specific genes improves diagnostic accuracy while optimizing cost and data management. As its applications expand in both clinical and research fields, considerations around limitations and ethical concerns remain important. Advancements in sequencing technology and bioinformatics will continue refining its utility, ensuring broader accessibility and improved outcomes.
Euformatics provides an end-to-end genomic data analysis platform that ensures accuracy, compliance, and efficiency in gene panel sequencing workflows. With tools like omnomicsQ for real-time quality control, omnomicsV for validation, and omnomicsNGS for variant interpretation, laboratories can streamline sequencing processes while meeting ISO 13485 and IVDR standards.
To make genomic analysis solutions more accessible, Euformatics offers a transparent pricing configurator where laboratories can customize costs based on their specific needs. Explore the Genomics Hub Price Configurator.
Book a demo today to see how Euformatics can optimize your gene panel sequencing workflows.
FAQ
What is Genetic Panel Testing?
A genetic panel test analyzes multiple genes simultaneously to detect variations associated with specific health conditions, hereditary disorders, or inherited traits. It can aid in diagnosing genetic diseases, assessing individual disease risk, guiding treatment decisions, and supporting informed family planning.
How Much Does a Full Genetic Panel Cost?
The cost of a full genetic panel varies widely, typically ranging from $300 to $5,000, depending on the complexity of the test and the number of genes analyzed. Prices might also differ based on the laboratory, the technology used, and whether insurance coverage is available.
What are incidental findings in gene panel testing?
Incidental findings are genetic variants discovered during testing that are unrelated to the original reason for the test but may still have potential health implications.
What Are the Advantages Gene Panel Testing?
Gene panel testing is cost-effective, faster than whole exome sequencing (WES) and whole genome sequencing (WGS), and focuses on clinically relevant genes, which simplifies data analysis and interpretation. .
What are the limitations of Gene Panel testing?
Gene panels are analyzing only a predefined set of genes, that may miss disease causing variants in genes that are not included in the panel. Additionally it can miss CNV and other structural variants which might be relevant for the disease.
References
- Kohno, Takashi. “Implementation of “clinical sequencing” in cancer genome medicine in Japan.” Cancer science 109, no. 3 (2018): 507-512.
- Nagahashi, Masayuki, Yoshifumi Shimada, Hiroshi Ichikawa, Hitoshi Kameyama, Kazuaki Takabe, Shujiro Okuda, and Toshifumi Wakai. “Next generation sequencing‐based gene panel tests for the management of solid tumors.” Cancer science 110, no. 1 (2019): 6-15.
- Patel, Keyur P., Roberto Ruiz-Cordero, Wei Chen, Mark J. Routbort, Kristen Floyd, Sergio Rodriguez, John Galbincea et al. “Ultra-Rapid Reporting of GENomic Targets (URGENTseq): clinical next-generation sequencing results within 48 hours of sample collection.” The Journal of Molecular Diagnostics 21, no. 1 (2019): 89-98.
